Summit Therapeutics SMMT Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Cash.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's cash & equivalents?
- Summit Therapeutics (SMMT) reported cash & equivalents of $8.24M in Q1 2026.
- How has Summit Therapeutics's cash & equivalents changed year-over-year?
- Summit Therapeutics's cash & equivalents increased by 7.2% year-over-year, from $7.68M to $8.24M.
- What is the long-term trend for Summit Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Summit Therapeutics's cash & equivalents has grown at a -24.4% compound annual growth rate (CAGR), from $66.42M to $16.37M.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid assets that can be accessed immediately.
- How do you interpret cash & equivalents?
- An increase indicates higher liquidity and ability to fund R&D, while a decrease may signal cash burn or upcoming capital needs.
- How does cash & equivalents compare across companies?
- Biotech peers typically maintain high cash balances to support multi-year clinical development cycles.